Dauntless Investment Group LLC purchased a new position in IO Biotech, Inc. (NASDAQ:IOBT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 747,646 shares of the company's stock, valued at approximately $688,000. IO Biotech accounts for approximately 0.7% of Dauntless Investment Group LLC's investment portfolio, making the stock its 13th biggest holding. Dauntless Investment Group LLC owned approximately 1.13% of IO Biotech as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Landscape Capital Management L.L.C. purchased a new stake in shares of IO Biotech during the 4th quarter worth approximately $407,000. Vontobel Holding Ltd. purchased a new stake in IO Biotech during the fourth quarter valued at approximately $30,000. XTX Topco Ltd bought a new position in shares of IO Biotech during the 4th quarter valued at approximately $26,000. Finally, Renaissance Technologies LLC lifted its position in IO Biotech by 22.5% in the fourth quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock worth $109,000 after buying an additional 21,800 shares during the last quarter. 54.76% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price target on shares of IO Biotech in a research note on Tuesday, April 1st. Piper Sandler upgraded IO Biotech to a "strong-buy" rating in a research report on Wednesday, March 12th.
Get Our Latest Research Report on IO Biotech
IO Biotech Stock Performance
IO Biotech stock traded down $0.03 during midday trading on Tuesday, hitting $0.93. 37,448 shares of the company's stock were exchanged, compared to its average volume of 156,612. IO Biotech, Inc. has a 12 month low of $0.66 and a 12 month high of $1.79. The company has a market cap of $60.94 million, a PE ratio of -0.68 and a beta of 0.08. The firm has a 50-day moving average of $0.95 and a two-hundred day moving average of $0.95.
IO Biotech Company Profile
(
Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Read More
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
